Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Idiopathic Parkinson Disease Clear all
Completed Not applicable Interventional Results available

ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease

NCT02263885
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial System
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

NCT00474058
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects

NCT01788696
View directory record Official record
Conditions
Parkinson Disease
Interventions
Group A - Early Imaging, Group B - Delayed Imaging
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jun 10, 2026, 5:39 AM EDT
Withdrawn Phase 2 Interventional

Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA

NCT05103618
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
[F-18] Fluorodopa Positron Emission Tomography, OM Meditation
Drug · Behavioral
Lead sponsor
Andrew Newberg
Other
Eligibility
25 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 10, 2026, 5:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Parkinson's Disease With Tear Fluid

NCT03037463
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
35 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

NCT01211587
View directory record Official record
Conditions
Parkinson's Disease With Cognitive Impairments
Interventions
safinamide, placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
45 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
9
States / cities
Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02242487
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 86 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

NCT00407212
View directory record Official record
Conditions
Parkinson's Disease
Interventions
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
301 participants
Timeline
2002 – 2003
U.S. locations
11
States / cities
Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

NCT03305809
View directory record Official record
Conditions
Lewy Body Dementia
Interventions
LY3154207, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 85 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Jun 10, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional

The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease

NCT07026734
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Deep brain stimulation surgery - GPi, Deep Brain Stimulation Surgery - STN
Procedure
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Not applicable Interventional

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease

NCT05862649
View directory record Official record
Conditions
Parkinson Disease
Interventions
NeuraLight
Other
Lead sponsor
NeuraLight
Industry
Eligibility
40 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

NCT02445651
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Results available

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

NCT02565628
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
PF-06669571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
New Haven, Connecticut • Hallandale, Florida • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Jun 10, 2026, 5:39 AM EDT
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

NCT02611167
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jun 10, 2026, 5:39 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

NCT03065192
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders
Interventions
VY-AADC01
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jun 10, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02240030
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301 Low Dose, CVT-301 High Dose, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jun 10, 2026, 5:39 AM EDT
Not listed Phase 4 Interventional

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

NCT01007630
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
The Parkinson's Institute
Other
Eligibility
Up to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Jun 10, 2026, 5:39 AM EDT